scholarly journals P2.07-021 A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC)

2017 ◽  
Vol 12 (11) ◽  
pp. S2423
Author(s):  
K. Yonesaka ◽  
K. Kudoh ◽  
S. Takamura ◽  
H. Sakai ◽  
R. Kato ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Checkpoint Molecule ◽  
Therapy Target

Exhaustive Review on Lung Cancers: Novel Technologies

2019 ◽  
Vol 15 (9) ◽  
pp. 873-883
Author(s):  
Sajad Khan ◽  
Shahid Ali ◽  
Muhammad
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Therapy ◽  
Small Cell ◽  
X Rays ◽  
Small Cell Lung ◽  
Microscopic Appearance ◽  
Lung Cancers ◽  
Novel Technologies

Background:Lung cancers or (Bronchogenic-Carcinomas) are the disease in certain parts of the lungs in which irresistible multiplication of abnormal cells leads to the inception of a tumor. Lung cancers consisting of two substantial forms based on the microscopic appearance of tumor cells are: Non-Small-Cell-Lung-Cancer (NSCLC) (80 to 85%) and Small-Cell-Lung-Cancer (SCLC) (15 to 20%).Discussion:Lung cancers are existing luxuriantly across the globe and the most prominent cause of death in advanced countries (USA & UK). There are many causes of lung cancers in which the utmost imperative aspect is the cigarette smoking. During the early stage, there is no perspicuous sign/symptoms but later many symptoms emerge in the infected individual such as insomnia, headache, pain, loss of appetite, fatigue, coughing etc. Lung cancers can be diagnosed in many ways, such as history, physical examination, chest X-rays and biopsy. However, after the diagnosis and confirmation of lung carcinoma, various treatment approaches are existing for curing of cancer in different stages such as surgery, radiation therapy, chemotherapy, and immune therapy. Currently, novel techniques merged that revealed advancements in detection and curing of lung cancer in which mainly includes: microarray analysis, gene expression profiling.Conclusion:Consequently, the purpose of the current analysis is to specify and epitomize the novel literature pertaining to the development of cancerous cells in different parts of the lung, various preeminent approaches of prevention, efficient diagnostic procedure, and treatments along with novel technologies for inhibition of cancerous cell growth in advance stages.

OR.88. IL-7/IL-7R alpha-Fc Immune Therapy for Non Small Cell Lung Cancer

2008 ◽  
Vol 127 ◽  
pp. S36
Author(s):  
Asa Andersson ◽  
Anshu Buttan ◽  
Raj Batra ◽  
Li Zhu ◽  
Steven Dubinett ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Therapy ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer

2021 ◽  
Author(s):  
Yabin Chen ◽  
Zhaoyuan Fang ◽  
Ying Tang ◽  
Yujuan Jin ◽  
Chenchen Guo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Therapy ◽  
Small Cell ◽  
Rna Seq ◽  
Small Cell Lung ◽  
Machine Learning Model ◽  
Novel Variant ◽  
Genomic Studies

Abstract Small cell lung cancer (SCLC) is highly invasive and lethal. Genomic studies are beginning to characterize its genetic determinants and heterogeneity. Here we performed RNA-Seq and whoe exome sequencing (WES) in 19 Chinese SCLC clinical tumor specimens. Integration with other two public cohorts (n = 129 for RNA-seq, n = 171 for WES), we carried out gene co-expression network analysis and classified into four subgroups: ASCL1-high, NEUROD1-high, a novel variant subtype with CCSP/CC10-high, and a fourth subtype with high expression of NOTCH family and inflammatory genes. We further found that this fourth subtype was characterized by overexpression of immune-related pathways and immunosuppressive factors, referred to as immune subtype. In addition to transcriptomic signatures, specific genomic alterations were also significantly enriched in each subtype. We successfully built a machine learning model to predict the subtypes of newly coming specimens based on transcriptomic data. In particular, we found that POU2F3 protein was effective in distinguishing immunotherapy patients, i.e. the immune subtype, which was further validated by an independent data of chemo-resistant patients received 2nd -line immunotherapy. Collectively, our work systematically studied the transcriptomic and genomic heterogeneity of SCLC, and characterized an immune subtype that displayed features of sensitivity to immune checkpoint-based therapies.

scholarly journals LAG-3 and PD-1/PD-L1 inhibitors might become a promising treatment for small cell lung cancer

2020 ◽  
Author(s):  
Yi Xu ◽  
Liping Zhang ◽  
Shengyu Wu ◽  
Wei Zhang ◽  
Yu Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Promising Treatment ◽  
Spss Software

Abstract Background Immune therapy has achieved notable success in cancer treatment. A novel immunocheckpoint, Lymphocyte activing gene-3 (LAG-3), has shown promising therapeutic efficacy in non-small cell lung cancer (NSCLC). However, literature about LAG-3 in small cell lung cancer (SCLC) is scarce. We performed statistical analysis to explore LAG-3 expression in SCLC patients, the correlation with programmed death 1 (PD-1) and programmed death ligand 1 (PD-1), the survival predictive significance, and the possibility of becoming an immunotherapeutic checkpoint of SCLC.Methods In this study, we included 102 patients diagnosed with SCLC. The expression of protein was evaluated by immunohistochemistry (IHC) staining. We performed all the correlation analysis and survival analysis with SPSS software (version 17.0; SPSS, Inc.; Chicago, IL)Results In SCLC, none tumor cell expressed LAG-3. LAG-3-positive TILs existed in 39.2% patients. The expression of LAG-3 was remarkably associated to PD-1 and PD-L1 expression on TILs (p = 0.006, p = 0.001). LAG-3 was the only prediction for TILs PD-L1 expression (ORs = 0.161, 95% CI: 0.063–0.412, p < 0.01). Although LAG-3-positive patients had relatively longer RFS, LAG-3 expression had no statistically significant differences in predicting prognosis (p = 0.088).Conclusions LAG-3 is an important immune checkpoint closely related to PD-1/PD-L1. There was significant correlation of LAG-3, PD-1, PD-L1 expression. LAG-3 and PD-1/PD-L1 inhibitors might be a promising immune therapy for SCLC.

scholarly journals Targeted and Immune Therapies in Non-small Cell Lung Cancer—Latest Advances

2017 ◽  
Vol 13 (02) ◽  
pp. 77
Author(s):  
Suresh S Ramalingam ◽  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Transmembrane Protein ◽  
Immune Therapy ◽  
Genetic Alterations ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Expert Interview

In recent years the treatment landscape of non-small cell lung cancer (NSCLC) has been transformed. The emergence of therapies targeting specific genetic alterations, such as epidermal growth factor (EGFR) mutations, as well as immune checkpoint inhibitors targeting the transmembrane protein programmed death-1 (PD1) and its ligand (PDL1), has increased the therapeutic options for patients with NSCLC. In an expert interview, Suresh S Ramalingam discusses recent advances in targeted and immune therapy and considers the role of chemotherapy within this rapidly evolving therapeutic paradigm.

scholarly journals Liquid Biopsy – Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer

Folia Medica ◽  
2021 ◽  
Vol 63 (6) ◽  
pp. 839-846
Author(s):  
Gabriela A. Raycheva ◽  
Hristo Y. Ivanov ◽  
Zhanet G. Grudeva-Popova
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Liquid Biopsy ◽  
Residual Disease ◽  
Immune Therapy ◽  
Small Cell ◽  
Therapeutic Monitoring ◽  
Genetic Profile ◽  
Small Cell Lung

Lung cancer is the leading cause of death from malignancy worldwide. Its heterogeneity and tumour biology make treatment considerably more difficult. The introduction of target molecules heralded the beginning of the personalized medicine which tailors medical treatments to the molecular and genetic profile of a patient. Liquid biopsy is an innovative, non-invasive method which is used both for diagnostic purposes and for therapeutic monitoring. Liquid biopsy has the potential to help manage non-small cell lung cancer throughout all stages of this cancer: screening, detection of minimal residual disease to guide adjuvant treatment, early detection of relapse, systemic treatment initiation, monitoring of response to targeted or immune therapy, and the emergence of resistance to applied treatment. At present, the study of circulating tumour DNA is used in clinical practice, but circulating tumour cells, miRNAs, exosomes, and platelets formed in the tumour also show promising results.

Sign in / Sign up

Export Citation Format

Share Document